Health insurance plans are changing how they cover GLP-1 drugs for weight loss to rein in costs, forcing doctors and patients ...

The 40-year-old comedian had a major wake-up call during the pandemic. Now he’s walking to the gym, eating apples instead of ...

Eli Lilly and Company today announced that data from studies of orforglipron, insulin efsitora alfa, tirzepatide (Zepbound and Mounjaro), retatrutide, eloralintide and bimagrumab will be presented at ...

If fillers are about retaining youth, Ozempic is about nailing the metabolism — with needles doing the heavy lifting ...

Weight-loss medications continue to grow in popularity as an anti-obesity tool — but are some more effective than others? The ...

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy.

A new report from FAIR Health reveals the extent to which weight loss medications such as Ozempic and Mounjaro are growing in ...

The vitamin C serum is TruSkin’s best-selling and reviewed product for a reason. A purposeful balance of botanical-infused ...

Eli Lilly will spend more than $5 billion to expand an Indiana manufacturing site and eventually make more doses of its popular weight-loss and diabetes treatments, Zepbound and Mounjaro.

The US Food and Drug Administration (FDA) has declared an end to the shortage of tirzepatide, the active ingredient in Eli Lilly’s popular weight loss medication Zepbound and diabetes drug Mounjaro.

Eli Lilly's drive to provide as many treatment options as possible for its weight-loss drug Zepbound has continued with the launch of new high-dose vials sold at a $150 discount to its auto ...